Clariscan™ (gadoteric acid)

Clariscan™ (gadoteric acid) is a macrocyclic gadolinium-based contrast agent, expertly manufactured by GE Healthcare, used to enhance visualization in MRI procedures across a range of indications

Diclaimer : Not all pack sizes may be registered in your country. Please contact us for more information.

Support
At a glance

Macrocyclic structure

Macrocyclic, ionic chelate provides high kinetic and themodynamic stability1

Expertly manufactured

Quality manufacture and delivery, expertly managed by GE for greatest control

Established tolerability

Over 17 million patient administrations, with low level of adverse events2,3

Convenient packaging options

Vials, prefilled syringes and +PLUSPAK bottles in a range of volumes
ABOUT CLARISCAN

Clariscan is a macrocyclic, general-purpose GBCA. Used to enhance over 17 million MRI procedures globally since launch, Clariscan is manufactured in-house by GE Healthcare in a range of packaging options and has a well-established tolerability profile3

STRUCTURE

Gadoteric acid: the only macrocylic, ionic molecule

Stability refers to how tightly the gadolinium ion is bound to the chelating molecule and how likely it is to dissociate. Gadoteric acid is the only macrocyclic, ionic molecule across all gadoliunium-based contrast agents. In vitro data suggest that combining a macrocyclic structure for high kinetic stability, with ionicity for thermodynamic stability, may help to reduce the potential risk of gadolinium dissociation.1
PACKAGING

Meeting procedural needs, with packaging that prioritises your workplace safety and efficiency

Clariscan offers a range of packaging:
  • Glass vials: 5, 10 and 20 mL
  • Clear plastic prefilled syringes: 10 and 20 mL

    • Disclaimer : Not all pack sizes may be registered in your country. Please contact us for more information.
COMMITMENT

Keeping production of Clariscan in-house, so you can be assured standards are maintained from start to finish

GE Healthcare has invested over $385M since 2013 in expansion of our manufacturing capacity to meet growing demand for our contrast agents. All our manufacturing sites are cGMP-accredited and we work closely with regulatory agencies globally to ensure quality supply.7
REFERENCES
  1. 1. Port M et al. Biometals. 2008;21(4):469-490.
  2. 2. GE Healthcare Data on File, Safety Profile Clariscan August 2022
  3. 3. Clariscan Summary of Product Characteristics, UK, GE Healthcare, April 2022.
  4. 4. Marshall G. Radiography 2008; 14: 128-34.
  5. 5. Gricar J et al. Radiol Manage 2007; SEP/OCT: 34-42.
  6. 6. Dhaliwal H et al. Int J Life Cycle Assess 2014; 19: 1965-73.
  7. 7. GE Healthcare Data on File, Investment 2021.
Dotarem is a trademark of Guerbet LLC.
 

Prescribing Information

Please click here for Clariscan prescribing information

Adverse events should be reported
Reporting forms and information can be found at: yellowcard.mhra.gov.uk
Adverse events should also be reported to GE Healthcare at:
gpv.drugsafety@ge.com

JB00595XY